Literature DB >> 9830391

Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy.

R Rogers1, R Prpic.   

Abstract

We report two cases where the addition of mibefradil to long term beta-blocker therapy in managing hypertension produced profound symptomatic bradycardia requiring cardiac pacing. Reports of a number of interactions between mibefradil and other cardioactive drugs have now led to its withdrawal from the market worldwide.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9830391

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


  3 in total

Review 1.  Informatics confronts drug-drug interactions.

Authors:  Bethany Percha; Russ B Altman
Journal:  Trends Pharmacol Sci       Date:  2013-02-13       Impact factor: 14.819

2.  Adverse effects using combined rate-slowing antihypertensive agents.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-06-20       Impact factor: 3.738

3.  The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil.

Authors:  Peter H Bui; Arnulfo Quesada; Adrian Handforth; Oliver Hankinson
Journal:  Drug Metab Dispos       Date:  2008-04-14       Impact factor: 3.922
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.